Clinical Decision Support System (CADIMS) for MS Diagnostic

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-10-11

Study Completion Date

2022-12-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Background The results obtained in clinical research led to a new paradigm for the treatment of patients affected with multiple sclerosis (MS): "no evidence of disease activity". This means having each patient monitored with high quality imaging. To this purpose, researchers have developed segmentation algorithms for automated reading of MRIs, facilitating longitudinal comparisons, and allowing an accurate assessment of the number and the volume of focal lesions. We have thus a powerful strategic biomarker for the treatment of MS.

Due to the relevance of comparing over time the evolution of lesions (lesion load) and brain atrophy, the French Society of Neuroradiology edited standardized national recommendations. The MS French Observatory (OFSEP) has adopted these recommendations, in order to harmonize exams for all patients all over the country. At an international level as well, MRI have been put at the heart of the therapeutic strategy.

Therefore, we need now to create the conditions able to implement, collect and analyze imaging data according to these recommendations.

This is the meaning of the MUSIC project, which aims to develop and assess a standardized monitoring MRI control tool for therapeutic decision.

CADIMS is this tool. It is based on an integration of several segmentation algorithms developed by INRIA and an image viewer developed by b\<\>com and included in a regional images-sharing server ETIAM Nexus. This tool is a help showing segmented brain T2 lesions, gadolinium-enhanced T1 lesions and news T2 lesions appeared from the previous MRI exam, in a multicenter clinical context.
2. Objective To evaluate the accuracy of MS lesions detection on cerebral MRI by comparing the CADIMS tool to the expert consensus.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Digitalization of Neurofunctional Tests Via a Mobile Application DAMS for Multiple Sclerosis Patients

NCT03148938

Multiple Sclerosis

COMPLETED NA

Study of Social Cognition by Morphological and Functional Imaging in Multiple Sclerosis Patients

NCT02290587

Multiple Sclerosis

COMPLETED NA

Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With Immunosuppressant

NCT01392872

Multiple Sclerosis, Relapsing-Remitting

COMPLETED NA

Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity

NCT07292480

Multiple Sclerosis (MS) - Relapsing-remitting

NOT_YET_RECRUITING NA

Multimodal MRI in Multiple Sclerosis (MS): Reliability and Follow Up

NCT00289159

Multiple Sclerosis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis, Relapsing-Remitting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥ 18 years-old
* Patient with relapsing-remitting multiple sclerosis, according to the 2010 Mc Donald's criteria
* EDSS\<4
* Disease duration \< 10 years
* To insure a clinical demand of 2 brain MRIs within 12 months of the installation of an immunomodulatory therapy
* MRI brain scanner acquired according to the OFSEP recommendations installation of an immunomodulatory therapy